Why the study?
Can mean platelet volume (MPV) serve as a biomarker for the risk and prognosis of atrial fibrillation and coronary artery disease?
Can mean platelet volume (MPV) serve as a biomarker for the risk and prognosis of atrial fibrillation and coronary artery disease?
Answers are grounded in this paper and cite their sources.
Mean platelet volume (MPV) is a promising, easily accessible biomarker for predicting ischemic stroke risk in atrial fibrillation and clinical outcomes following PCI in coronary artery disease.
Platelets are essential for progression of atherosclerotic lesions, plaque destabilization, and thrombosis. They secrete and express many substances that are crucial mediators of coagulation, inflammation, and atherosclerosis. Mean platelet volume (MPV) is a precise measure of platelet size, and is routinely reported during complete blood count analysis. Emerging evidence supports the use of MPV as a biomarker predicting the risk of ischemic stroke in patients with atrial fibrillation, and as a guide for prescription of anticoagulation and rhythm-control therapy. In addition, MPV may predict the clinical outcome of percutaneous coronary intervention (PCI) in patients with coronary artery disease and indicate whether additional adjunctive therapy is needed to improve clinical outcomes. This review focuses on the current evidence that MPV may be a biomarker of the risk and prognosis of common heart diseases, particularly atrial fibrillation and coronary artery disease treated via PCI.
No takes yet. Share an insight, caveat, or question.
Choi et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: